Literature DB >> 29891734

LVP keratoprosthesis: anatomical and functional outcomes in bilateral end-stage corneal blindness.

Sayan Basu1, Ritu Nagpal2, Juan Carlos Serna-Ojeda2, Swapnil Bhalekar2,3, Bhupesh Bagga2, Virender Sangwan2.   

Abstract

PURPOSE: To describe the anatomical and functional outcomes of the novel LVP keratoprosthesis (Kpro), developed as an alternative to the modified osteo-odonto keratoprosthesis (MOOKP), in eyes with end-stage corneal blindness where conventional corneal surgeries are contraindicated.
METHODS: This prospective case series included 58 eyes of 56 patients (12 children and 44 adults) with severe bilateral keratopathy and completely dry, dermalised ocular surfaces who underwent unilateral LVP Kpro implantation from 2012 to 2016. In this two-stage procedure, an ocular surface labial mucous membrane grafting was performed, followed for 3 months by the implantation of the device under the engrafted mucosal flap. The primary outcome measures were anatomical retention rate and improvement in best corrected visual acuity (BCVA). The secondary outcome measure was rate of occurrence of complications.
RESULTS: Mean postoperative follow-up was 2.5±1.1 years. Kaplan-Meier survival analysis showed an anatomical retention rate of 90.8%±3.9% at 1 year, 80%±5.7% at 2 years and 76.6%±6.5% at 3-5 years. The survival rates were comparable in children and adults (91% vs 72% at 5 years, p=0.258). About 61.5% of eyes maintained 20/400 or better vision and median BCVA improved from perception of light to 20/70 at 1 year postoperatively (p<0.0001). Complications like retroprosthetic membrane formation, glaucoma, vitritis, endophthalmitis and panophthalmitis occurred in 43%, 26%, 22%, 12% and 3% of the eyes, respectively.
CONCLUSION: The LVP Kpro is an effective procedure for the treatment of end-stage corneal blindness in completely dry eyes. The LVP Kpro can be particularly useful in situations where the MOOKP is contraindicated or difficult to perform. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cornea; ocular surface; treatment surgery

Year:  2018        PMID: 29891734     DOI: 10.1136/bjophthalmol-2017-311649

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

Review 1.  A Review of the Diagnosis and Treatment of Limbal Stem Cell Deficiency.

Authors:  Anahita Kate; Sayan Basu
Journal:  Front Med (Lausanne)       Date:  2022-05-25

2.  Endophthalmitis with opaque cornea managed with primary endoscopic vitrectomy and secondary keratoplasty: Presentations and outcomes.

Authors:  Vivek P Dave; Rajeev R Pappuru; Mohammad A Khader; Sayan Basu; Mudit Tyagi; Avinash Pathengay
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

Review 3.  An Evidence-Based Strategic Approach to Prevention and Treatment of Dry Eye Disease, a Modern Global Epidemic.

Authors:  Pragnya R Donthineni; Swapna S Shanbhag; Sayan Basu
Journal:  Healthcare (Basel)       Date:  2021-01-17

4.  Keratoprosthesis: Current Choices and Future Development.

Authors:  Mehran Zarei-Ghanavati; Christopher Liu
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Nov-Dec

Review 5.  Chronic cicatrizing conjunctivitis: A review of the differential diagnosis and an algorithmic approach to management.

Authors:  Jayesh Vazirani; Pragnya R Donthineni; Sahil Goel; Sayali S Sane; Sheetal Mahuvakar; Purvasha Narang; Swapna S Shanbhag; Sayan Basu
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

Review 6.  Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA.

Authors:  Derek Metcalfe; Omer Iqbal; James Chodosh; Charles S Bouchard; Hajirah N Saeed
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.